$ABOS News

Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer’s Data Approach

Acumen Pharmaceuticals Q3 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) Narrows Q3 Loss as ALTITUDE-AD Readout Looms

Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day - Slideshow

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...

Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary